Contributor: Juan Manuel Sarasua

Juan Manuel Sarasua is a Brussels-based science journalist covering science, health, and technology topics for several publications in Europe, Latin America, and the United States. He currently covers COVID-19 news for the medicine portal Medscape. Biologist by training, he also has over 15 years of experience creating science communicating strategies for scientists, universities and research institutions in Europe, such as the European Research Council (ERC), the University College London (UCL) and the Centre for Genomic Regulation (CRG).

Coronavirus Covid-19 treatment illustration banner

The key role of antivirals in COVID-19 treatment

A few weeks after the SARS-CoV-2 was identified by Chinese researchers as the cause of ‘COVID-19’, an antiviral called remdesivir, originally used during the 2014 Ebola outbreak, came into play as the first available option to treat patients with coronavirus disease 2019 (COVID-19). Even if the approval process for remdesivir caused some controversy, experts consider the combined use of antivirals and other drugs a promising solution for treatment of Covid-19.

Coronavirus Covid-19 treatment illustration banner

A scientist’s opinion : Interview with Prof Martijn van Hemert about covid-19 treatment

Interview with Martijn van Hemert, Associate professor and Principal Investigator in molecular virology and antiviral strategies at the Leiden University Medical Center. In recent years, his group has mainly been studying the Chikungunya and Zika viruses, but in the past he has also studied SARS-CoV. Since February 2020, he has shifted his focus to research ...

Coronavirus Covid-19 treatment illustration banner

A scientist’s opinion : Interview with Dr Juan Pablo Horcajada about covid-19 treatment

Interview with Juan Pablo Horcajada, MD. is Head of the Department of Infectious Diseases and General Coordinator of the COVID-19 Service at the Hospital del Mar, Barcelona. Remdesivir is the first drug approved by the EMA to be used as part of the treatment of COVID-19 patients. How’s the use of this antiviral in your ...